Skip to content ↓

Topic

Bioengineering and biotechnology

Download RSS feed: News Articles / In the Media / Audio

Displaying 16 - 30 of 175 news clips related to this topic.
Show:

The Boston Globe

Ginkgo Bioworks, a biotech company founded by Jason Kelly BS ’03, PhD ’08, Reshma Shetty PhD ‘08, Barry Canton PhD ’08, Austin Che PhD ’08 and Professor Tom Knight, is working to develop synthetic fragrances, reports Scott Kirsner for The Boston Globe.

New Scientist

Researchers at the McGovern and Broad Institutes have developed a bacterial "nanosyringe" that can inject large proteins into specific cells in the body, which could lead to safer and more effective treatments for a variety of conditions, including cancer, reports Michael Le Page for New Scientist. “The fact that this can load a diversity of different payloads of different sizes makes it unique amongst protein delivery devices,” says graduate student Joseph Kreitz.

Scientific American

Ingrid Wickelgren at Scientific American highlights a new study from researchers at the McGovern and Broad Institutes, in which they used a bacterial ‘nanosyringe’ to inject large proteins into human cells. “The syringe technology also holds promise for treating cancer because it can be engineered to attach to receptors on certain cancer cells,” writes Wickelgren.     

Scientific American

Prof. Ritu Raman speaks with Scientific American about her work “building machines that we call bio-hybrid because they're part biological and part made out of synthetic materials. The biological robots that we're building are powered by muscle tissue so that every time the muscle contracts, you could get something that looks like movement.”

The Boston Globe

Boston Globe reporter Ryan Cross spotlights Chroma Medicine, a biotech startup co-founded by MIT researchers that is “developing a new class of gene editing technologies that could control how our genetic code is read without changing the code itself.” Cross explains that Chroma Medicine’s technology could “have broad applications for treating both rare and common diseases.”

Forbes

Deepak Dugar MBA ’13, PhD ’13 founded Visolis, a biomanufacturing company developing carbon-negative, high-performance materials, reports John Cumbers for Forbes. “We use biology to make platform molecules. And then we use chemistry to turn them into a lot of different products. Because of this unique combination, we have an advantage both in terms of market as well as cost of technology development,” says Dugar.

Forbes

Asimov - an MIT spinout co-founded by Prof. Christopher Voigt, Alec Nielsen PhD ’16, Raja Srinivas PhD ’16, and Boston University Prof. Douglas Densmore - is a biotechnology company developing tools to design living systems, reports John Cumbers for Forbes. “Every cell is capable of computing. Perceiving environmental signals, information processing, turning genes on and off,” says Nielsen. “The ability to engineer this gift of evolution is, in my view, going to be the most meaningful and impactful technology that humans have ever developed.”

Forbes

Harry McNamara PhD ’19, David Heller ’18, and Shara Ticku co-founded C16 Biosciences, a biotechnology company that uses synthetic biology to address environmental concerns, reports John Cumbers for Forbes. The company “wants to replace conflict palm oil with a sustainable alternative made in yeast using precision fermentation,” writes Cumbers.

NPR

Lydia Villa Komaroff PhD ’75 speaks with NPR reporter Emily Kwong about her work in gene editing. Biotechnology and genetic engineering were “enormously impactful,” says Komaroff. “So impactful that molecular biology pretty much disappeared as a field, it has become a tool that is of use in every field of biology and medicine today.”

The Boston Globe

Jake Becraft PhD ’19 and former postdoctoral associate Tasuku Kitada co-founded Strand Therapeutics, a biotech firm developing mRNA therapies for cancer, reports Ryan Cross for The Boston Globe. They created “a way to activate mRNA in the presence of particular microRNAs – a much more useful application for therapies,” writes Cross. 

Forbes

Forbes reporter John Cumbers spotlights Jasmina Aganovic ’09 for her work in combining biotechnology with skincare. "Biotechnology enables us to expand the ingredient palette of the beauty industry to molecules in all parts of the tree of life, ethically and sustainably," says Aganovic.

Scientific American

MIT scientists have developed a miniature antenna that could one day be used to help safely transmit data from within living cells “by resonating with acoustic rather than electromagnetic waves,” reports Andrew Chapman for Scientific American. “A functioning antenna could help scientists power, and communicate with, tiny roving sensors within the cell,” writes Chapman, “helping them better understand these building blocks and perhaps leading to new medical treatments.”

New Scientist

Prof. Kevin Esvelt speaks with New Scientist reporter Michael Le Page about his work outlining a roadmap to help counter the risk posed by pandemic terrorism. “The message is, this is serious but this is totally solvable,” says Esvelt.

Wired

Research from Synlogic, a biotech company founded by Profs James Collins and Timothy Lu, has found that it’s the company’s engineered bacteria could provide some benefit to patients with a rare genetic disease, reports Emily Mullin for Wired. “Similar to how you might program a computer, we can tinker with the DNA of bacteria and have them do things like produce a drug at the right time and the right place, or in this case, break down a toxic metabolite,” says Lu.

The Boston Globe

Scientists from MIT, Duke and Stanford have developed a new technique to make gene therapies safer and more effective, reports Ryan Cross for The Boston Globe. “It’s about making these therapies much smarter and programmable,” says Jonathan S. Gootenberg, a research scientist at the McGovern Institute.